Search the Newsreel

BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 …

GRAL 1-WEEK DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL)

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about …

Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly …

Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. – GRAL

Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more …

GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false …

$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors

BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe …

AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, …

Epigral Eyes ₹1,300-₹1,500 Cr Peak Revenue from ₹600 Cr Dahej Expansion Plan

GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations

A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead …

GRAL 集體訴訟的最後期限：全球頂尖法律事務所 ROSEN 鼓勵 GRAIL, Inc. 投資者在對 GRAL 提出證券集體訴訟的重要的截止日期 8 月 4 日之前聘請律師

紐約, July 27, 2026 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒在 2025 年 5 月 13 日至 2026 年 2 月 19 日（包括首尾兩日，下稱「集體訴訟期」）期間購買了 GRAIL, Inc. (NASDAQ: GRAL) 普通股之人士注意，重要的首席原告截止日期為 2026 年 8 月 4 日。 影響：如果您在集體訴訟期間購買 GRAIL 普通股，您可能有權透過勝訴收費安排獲得賠償，而毋須支付任何自付費用或訟費。 下一步行動：如欲加入 GRAIL 集體訴訟，請造訪 https://rosenlegal.com/cases/grail-inc/join 或免費致電 866-767-3653 …

GRAIL Inc Revenue Breakdown – HAN:NL0

GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top segment, Screening, showing an increase from the previous year's 104.93 million EUR. The United States was the largest contributor to the …

Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail

Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers. These solutions, available from January 1, 2027, will offer virtual cancer navigation, support, and multi-cancer early detection to Priority Health's 1.4 million members. The aim …

GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff …

HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer …

$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability …

How Grail Inc Com (GRAL) Affects Rotational Strategy Timing

The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance levels and an exceptional short setup with significant downside potential against low risk. Several institutional …

GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted …

Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

SueWallSt is announcing a securities class action lawsuit against Grail, Inc. (GRAL) on behalf of shareholders who experienced significant losses after the company's NHS-Galleri trial failed to meet its primary endpoint. Investors are encouraged to seek lead plaintiff status by August 4, 2026, though …

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against GRAIL, Inc. (GRAL)

Bernstein Liebhard LLP has announced a securities class action lawsuit filed against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements, leading to artificially inflated …

GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026

Bernstein Liebhard LLP reminds investors of GRAIL, Inc. (NASDAQ: GRAL) that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, causing …

GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026

Levi & Korsinsky reminds investors of Grail, Inc. (NASDAQ: GRAL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is August 4, 2026. This lawsuit follows a significant stock drop after Grail's NHS-Galleri trial failed its primary endpoint, resulting …

INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman

Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged securities law violations in connection with its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL misled investors about the trial's design and efficacy, particularly regarding the adequacy of the three-year follow-up period, leading to …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. …

Enterprise value to EBIT forward of GRAIL, Inc. – NASDAQ:GRAL

This article from TradingView provides a financial metric for GRAIL, Inc. (NASDAQ: GRAL), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. The content is primarily a title and navigational elements, indicating the company's listing on the Nasdaq Stock Market under …

Lawsuit Notice: $GRAL Legal News: GRAIL, Inc. Trial Results and 50% Stock Drop Trigger Securities Fraud Class Action

Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50.55% stock drop on February 20, 2026, after the trial failed …

Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of Grail, Inc. (GRAL) about an upcoming August 4, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Grail made misleading statements during the Class Period of May …

GRAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”), of the important August …

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false or misleading statements regarding its NHS Galleri …

GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Levi & Korsinsky, LLP has issued a shareholder alert for Grail, Inc. (NASDAQ: GRAL) investors, announcing a securities class action lawsuit. The lawsuit alleges that Grail misled investors regarding its NHS-Galleri trial, which was projected to achieve a statistically significant reduction in late-stage cancers …

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

Hagens Berman is investigating a securities class action against GRAIL, Inc. (GRAL) following a $2.2 billion market cap wipeout after its NHS-Galleri cancer screening trial failed to meet its primary endpoint. The lawsuit alleges that GRAIL misled investors by concealing insufficient trial design and …

GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GRAIL, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and certain officers. The lawsuit claims that defendants made misleading statements between May 13, 2025, and February 19, 2026, regarding the likelihood of success in Grail's NHS-Galleri trial. Investors …

GRAIL, Inc. Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit

The Rosen Law Firm reminds purchasers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, that they have an opportunity to lead a securities fraud class action lawsuit. Investors who bought GRAIL common stock during this period can …

GRAIL, INC. DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,

The Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made false …

GRAL INVESTOR DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against GRAIL, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased GRAL common stock between May 13, 2025, and February 19, 2026, and suffered substantial losses, have until …

GRAIL, Inc. (GRAL) director receives 276 deferred stock units as fees

GRAIL, Inc. director William J. Chase was granted 276 deferred stock units on July 15, 2026, as compensation for director fees, totaling $20,568.49. These units, priced at $74.36 per share, vested immediately, increasing his direct holdings to 42,978 shares. This transaction was reported in …

Director at GRAIL, Inc. (GRAL) receives 427 deferred stock units in fee swap

GRAIL, Inc. Director Gregory L. Summe was granted 427 deferred stock units (DSUs) as compensation, valued at $31,787.67, in lieu of cash director fees. The DSUs, priced at $74.36 per unit, vested immediately on July 15, 2026, and increased his direct holdings to 45,672 …